Boehringer Ingelheim and MD Anderson Form Unique Virtual Research and Development Center to Rapidly Advance New Cancer Therapies
Advertisement
-- New potential gastrointestinal and lung cancer therapies from Boehringer Ingelheim's innovative oncology pipeline will be combined with the patient-driven drug-development capabilities at MD Anderson